Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline's reported carbon emissions
In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 44,000,000 kg CO2e for Scope 2 globally. In the UK, GSK's combined Scope 1 and 2 emissions were about 92,000,000 kg CO2e. The company has set ambitious climate targets, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030 and across its full value chain (all scopes) by 2045. GSK has committed to significant reductions, targeting an 80% decrease in absolute Scope 1 and 2 emissions by 2030 from a 2020 baseline, and a 90% reduction by 2045. For Scope 3 emissions, GSK aims for an 80% reduction by 2030 and 90% by 2045, also from a 2020 baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to keep global warming below 1.5°C. In recent years, GSK has achieved a 15% reduction in Scope 1 and 2 emissions from 2020 to 2021. The company has also committed to reducing its carbon footprint by at least 90% by 2045, with any remaining emissions to be offset through high-quality solutions. GSK's climate commitments reflect its dedication to sustainability and responsible business practices, as outlined in its various reports and initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
